ArticleNanomedicine : nanotechnology, biology, and medicine2014
Protein corona composition does not accurately predict hematocompatibility of colloidal gold nanoparticles.
Article in Nanomedicine : nanotechnology, biology, and medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 162 citations in OpenAlex.
- The protein corona at the nano-bio interface: the need for standardized methodology and opportunities for neurodegenerative disease intervention.RSC advances · 2026Review
- Tumor radiosensitization with gold nanoparticles: evolving strategies to improve tumoral gold uptake and catalyze future clinical translation.ACS nano medicine · 2026Article
- Isomeric Differences in Nanoparticle's Surface Chemistry Alter Macrophage Interactions In Vitro Due to Protein Corona.ACS omega · 2025Article
- Immunomodulatory Effects of Gold Nanoparticles: Impacts on Immune Cells and Mechanisms of Action.Nanomaterials (Basel, Switzerland) · 2025Review
- tRNA-Derived Small RNA Accelerates Tumorigenesis through Crosstalk with Tumor-Associated Macrophages, and Downregulation with Cell Membrane-Modified Polymer Nanoparticles Enables Treatment Response.ACS applied materials & interfaces · 2025Article
- Designing Polyelectrolyte Microneedles Based on Borylated Poly(β-aminoester) Polymers To Enhance Transdermal pH-Controlled Delivery of Nucleic Acids.ACS applied polymer materials · 2024Article
- Advancements in Nanoparticle Characterization.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Entry of nanoparticles into cells and tissues: status and challenges.Beilstein journal of nanotechnology · 2024Article
- Surface antibody changes protein corona both in human and mouse serum but not final opsonization and elimination of targeted polymeric nanoparticles.Journal of nanobiotechnology · 2023Article
- Quantitative comparison of the protein corona of nanoparticles with different matrices.International journal of pharmaceutics: X · 2022Article
- Gold Nanoparticles Contact with Cancer Cell: A Brief Update.International journal of molecular sciences · 2022Review
- Rosmarinic Acid-Loaded Polymeric Nanoparticles Prepared by Low-Energy Nano-Emulsion Templating: Formulation, Biophysical Characterization, and In Vitro Studies.Materials (Basel, Switzerland) · 2022Article
- The Relevance of Physico-Chemical Properties and Protein Corona for Evaluation of Nanoparticles Immunotoxicity-In Vitro Correlation Analysis on THP-1 Macrophages.International journal of molecular sciences · 2022Article
- To PEGylate or not to PEGylate: Immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives.Advanced drug delivery reviews · 2022Review
- Biomimetic phototherapy in cancer treatment: from synthesis to application.Drug delivery · 2021Review
- Impact of Protein Corona on the Biological Identity of Nanomedicine: Understanding the Fate of Nanomaterials in the Biological Milieu.Biomedicines · 2021Review
- Engineered Exosomes-Based Photothermal Therapy with MRI/CT Imaging Guidance Enhances Anticancer Efficacy through Deep Tumor Nucleus Penetration.Pharmaceutics · 2021Article
- Nanozyme for tumor therapy: Surface modification matters.Exploration (Beijing, China) · 2021Review
- Opportunities and challenges for the clinical translation of structured DNA assemblies as gene therapeutic delivery and vaccine vectors.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2021Review
- Understanding the relevance of protein corona in nanoparticle-based therapeutics and diagnostics.RSC advances · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Proteins bound to nanoparticle surfaces are known to affect particle clearance by influencing immune cell uptake and distribution to the organs of the mononuclear phagocytic system. The composition of the protein corona has been described for several types of nanomaterials, but the role of the corona in nanoparticle biocompatibility is not well established. In this study we investigate the role of nanoparticle surface properties (PEGylation) and incubation times on the protein coronas of colloidal gold nanoparticles. While neither incubation time nor PEG molecular weight affected the specific proteins in the protein corona, the total amount of protein binding was governed by the molecular weight of PEG coating. Furthermore, the composition of the protein corona did not correlate with nanoparticle hematocompatibility. Specialized hematological tests should be used to deduce nanoparticle hematotoxicity. From the clinical editor: It is overall unclear how the protein corona associated with colloidal gold nanoparticles may influence hematotoxicity. This study warns that PEGylation itself may be insufficient, because composition of the protein corona does not directly correlate with nanoparticle hematocompatibility. The authors suggest that specialized hematological tests must be used to deduce nanoparticle hematotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.